Emilie Lereclus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emilie Lereclus has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Karl Balabanian
Université Paris Cité, Institut de Recherche Saint Louis, INSERM UMR1342, Paris, France
3 shared publications - Lin-Pierre Zhao
Université Paris Cité, Institut de Recherche Saint Louis, INSERM UMR1342, Paris, France
2 shared publications - Nicolas Dulphy
Université Paris Cité, Institut de Recherche Saint Louis, INSERM UMR1342, Paris, France
2 shared publications - Adrien Bigot
25Department of Internal Medicine, Hôpital de Tours, Tours, France
1 shared publication Aldric Manuel
26Department of Internal Medicine, Centre Hospitalier Annecy-Genevois, Annecy, France
1 shared publicationAlexandra Audemard-Verger
25Department of Internal Medicine, Hôpital de Tours, Tours, France
1 shared publication
Latest Publications
- 9 November 2026
- Published by Springer Nature in Leukemia
- p. 1-12
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells
Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease’s development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.
- 9 November 2026
- Published by Springer Nature in Leukemia
- p. 1-12
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells
Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease’s development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.
- 16 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1950-1963
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disorder caused by acquired somatic ubiquitin like modifier activating enzyme 1 (UBA1) mutations in hematopoietic stem cells, affecting peripheral myeloid and natural killer (NK) cells. Given the high rate of severe infections in patients with VEXAS, we hypothesized that NK-cell dysfunction contributes to this susceptibility. We conducted a comprehensive immune characterization of peripheral NK cells in patients with VEXAS (n = 40), patients with autoinflammatory diseases without UBA1 mutations (n = 22), and older sex-matched healthy controls (n = 16). Multiparameter phenotyping used cytometry by time-of-flight, single-cell RNA sequencing (scRNA-seq), whole-blood stimulation assays, and in vitro NK-cell cytotoxic assay. Peripheral NK cells in VEXAS were quantitatively and qualitatively impaired. Mass cytometry revealed reduced frequencies of mature cytotoxic CD56dim NK cells and expansion of the CD56high CD16dim subset. NK cells exhibited exhaustion features, including increased programmed cell death protein 1 expression, and reduced cytotoxic markers such as NKp46 and CD8α. scRNA-seq analysis showed decreased signatures of cytotoxicity and interleukin-2 (IL-2) and interferon gamma (IFN-γ) production, alongside increased inflammatory signatures. Whole-blood stimulation assays confirmed impaired IL-2, IFN-γ, and granzyme B production following Toll-like receptor 3 (TLR3), TLR4, and TLR7/TLR8 agonist stimulation. Extended NK phenotyping by flow cytometry confirmed reduced activating receptors’ expression and impaired IFN-γ production in VEXAS syndrome. Moreover, in vitro UBA1 inhibitors impaired NK-cell cytotoxic capacity and promote cell death. Finally, reduced NK-cell frequencies were independently associated with an increased risk of severe infections. These findings suggest that NK-cell dysfunction in VEXAS syndrome contributes to increased susceptibility to severe infections.
- 16 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1950-1963
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disorder caused by acquired somatic ubiquitin like modifier activating enzyme 1 (UBA1) mutations in hematopoietic stem cells, affecting peripheral myeloid and natural killer (NK) cells. Given the high rate of severe infections in patients with VEXAS, we hypothesized that NK-cell dysfunction contributes to this susceptibility. We conducted a comprehensive immune characterization of peripheral NK cells in patients with VEXAS (n = 40), patients with autoinflammatory diseases without UBA1 mutations (n = 22), and older sex-matched healthy controls (n = 16). Multiparameter phenotyping used cytometry by time-of-flight, single-cell RNA sequencing (scRNA-seq), whole-blood stimulation assays, and in vitro NK-cell cytotoxic assay. Peripheral NK cells in VEXAS were quantitatively and qualitatively impaired. Mass cytometry revealed reduced frequencies of mature cytotoxic CD56dim NK cells and expansion of the CD56high CD16dim subset. NK cells exhibited exhaustion features, including increased programmed cell death protein 1 expression, and reduced cytotoxic markers such as NKp46 and CD8α. scRNA-seq analysis showed decreased signatures of cytotoxicity and interleukin-2 (IL-2) and interferon gamma (IFN-γ) production, alongside increased inflammatory signatures. Whole-blood stimulation assays confirmed impaired IL-2, IFN-γ, and granzyme B production following Toll-like receptor 3 (TLR3), TLR4, and TLR7/TLR8 agonist stimulation. Extended NK phenotyping by flow cytometry confirmed reduced activating receptors’ expression and impaired IFN-γ production in VEXAS syndrome. Moreover, in vitro UBA1 inhibitors impaired NK-cell cytotoxic capacity and promote cell death. Finally, reduced NK-cell frequencies were independently associated with an increased risk of severe infections. These findings suggest that NK-cell dysfunction in VEXAS syndrome contributes to increased susceptibility to severe infections.
- Open Access
Plasma cell heterogeneity is driven by type of immune challenge
Plasma cells play an essential role in humoral immunity, but many questions remain regarding the heterogeneity of this population, both in terms of ontogeny and involvement in the immune response. In this work, we have identified 5 subsets of plasma cells in human and mouse lymphoid tissues. These subpopulations were distinguished by differential expression of CD62L, CXCR4, FcγRIIb and CD93. The antigenic context as well as the B cell of origin directed plasma cell differentiation towards specific subtypes that display distinct migratory and survival abilities in vivo . Altogether, ours results unveil that plasma cell phenotypic and functional heterogeneity relies on intrinsic imprinting during B cell activation.
Open AccessPlasma cell heterogeneity is driven by type of immune challenge
Plasma cells play an essential role in humoral immunity, but many questions remain regarding the heterogeneity of this population, both in terms of ontogeny and involvement in the immune response. In this work, we have identified 5 subsets of plasma cells in human and mouse lymphoid tissues. These subpopulations were distinguished by differential expression of CD62L, CXCR4, FcγRIIb and CD93. The antigenic context as well as the B cell of origin directed plasma cell differentiation towards specific subtypes that display distinct migratory and survival abilities in vivo . Altogether, ours results unveil that plasma cell phenotypic and functional heterogeneity relies on intrinsic imprinting during B cell activation.